vimarsana.com

Latest Breaking News On - Ocular therapeutix - Page 1 : vimarsana.com

Sanjay Nayak Sells 2,274 Shares of Ocular Therapeutix, Inc (NASDAQ:OCUL) Stock

Ocular Therapeutix, Inc. (NASDAQ:OCUL – Get Free Report) insider Sanjay Nayak sold 2,274 shares of Ocular Therapeutix stock in a transaction on Thursday, May 23rd. The shares were sold at an average price of $5.84, for a total value of $13,280.16. Following the sale, the insider now directly owns 178,026 shares of the company’s stock, […]

New yorkUnited statesSanjay nayakPiper sandlerRaymond james associatesOcular therapeutix incRafferty asset managementYork state common retirement fundRaymond james financial services advisors incBarclays plcSecurities exchange commissionOcular therapeutixGet free reportExchange commissionJames financial services advisorsOcular therapeutix daily

Experts weigh current, future options for AMD management

Experts weigh current, future options for AMD management
healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.

United statesCleveland clinicBaylor college of medicinePeterk kaiserBaruchd kuppermannTheravance biopharmaIveric bioArmando monroigKlin monbl augenheilkdChristinay wengGenentech rocheSamsung bioepisAllergan abbvieUrsula schmidt erfurthJaclynl kovachBascom palmer eye institute baruchd kuppermann

Analysts Set Ocular Therapeutix, Inc (NASDAQ:OCUL) Price Target at $15 17

Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL – Get Free Report) have been given a consensus recommendation of “Moderate Buy” by the six brokerages that are covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The average […]

United statesPiper sandlerTower research capitalEssex investment management coAmeritas investment partners incOcular therapeutix incBarclays plcOcular therapeutixGet free reportMarketbeat ratingsSummer road llcInvestment partnersResearch capitalEssex investment managementInvestment managementGet free

OCUL Stock Earnings: Ocular Therapeutix Misses EPS, Misses Revenue for Q1 2024

OCUL Stock Earnings: Ocular Therapeutix Misses EPS, Misses Revenue for Q1 2024
biztoc.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biztoc.com Daily Mail and Mail on Sunday newspapers.

Market newsStock adviceOcular therapeutixOcular therapeutix missesMisses revenue

Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

Zhongwen justin tangXiaopeng jeff caiOcular therapeutix incCompensation committee of ocularVice presidentData operationsCompensation committeeStock incentive planNasdaq listing ruleNasdaq global marketStock incentiveOcular therapeutix

vimarsana © 2020. All Rights Reserved.